Deutsche Bank AG Sells 13,594 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Deutsche Bank AG trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.8% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 186,801 shares of the biopharmaceutical company's stock after selling 13,594 shares during the quarter. Deutsche Bank AG owned 0.15% of Catalyst Pharmaceuticals worth $4,530,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Cambridge Investment Research Advisors Inc. bought a new stake in Catalyst Pharmaceuticals during the 1st quarter worth approximately $484,000. Principal Financial Group Inc. boosted its position in shares of Catalyst Pharmaceuticals by 2.8% in the first quarter. Principal Financial Group Inc. now owns 617,506 shares of the biopharmaceutical company's stock valued at $14,975,000 after acquiring an additional 17,018 shares during the period. Spire Wealth Management raised its stake in Catalyst Pharmaceuticals by 27.7% during the first quarter. Spire Wealth Management now owns 18,429 shares of the biopharmaceutical company's stock worth $447,000 after acquiring an additional 4,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Catalyst Pharmaceuticals by 65.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 35,334 shares of the biopharmaceutical company's stock worth $857,000 after acquiring an additional 13,915 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in Catalyst Pharmaceuticals during the first quarter worth about $2,343,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Trading Up 0.8%

Shares of CPRX traded up $0.16 during trading hours on Thursday, reaching $20.50. The stock had a trading volume of 445,211 shares, compared to its average volume of 1,309,855. The firm has a 50-day simple moving average of $21.41 and a 200 day simple moving average of $22.64. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of 12.42, a P/E/G ratio of 0.82 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.00 and a 12 month high of $26.58.

Insider Activity

In other news, insider Preethi Sundaram sold 2,324 shares of the business's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total transaction of $61,376.84. Following the transaction, the insider directly owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. The trade was a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.40% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on CPRX. Zacks Research downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Wall Street Zen downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $33.20.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.